CANADA: Tilray Canada Ltd., a medical cannabis leader committed to advancing scientific knowledge of cannabinoids, shared preliminary data today from the Tilray Observational Patient Study (TOPS), a Tilray-sponsored survey of medical cannabis patients using Tilray products currently underway at 18 different medical clinics in five provinces in Canada. As Canada’s largest national medical cannabis longitudinal study, TOPS collects critical data from participating patients that can help shape further research and inform physicians, healthcare providers, and policymakers.
There are currently 1,300 patients enrolled in TOPS. This preliminary data set is based on 573 patients enrolled on or before December 1, 2017 who have completed at least one post-baseline visit. For these patients:
- Baseline opioid use was reported by 32% of patients (n=179) and dropped to 13.6% (n=30) of total study participants at 6 months.
- The odds ratio of using opioids relative to baseline was 0.44 at one month, 0.24 at three months and 0.12 at six months (p<0.001).
- Average mgs per day of opioid use among the 156 patients using opioids at baseline that completed a six-month follow-up dropped from an average of 187.3mgs (SD= 452.7) to 47.9 mgs (SD=142.4) per day, a 74.4% decline, with 51.3% of patients ceasing opioid use altogether.
“The high rate of cannabis use for the treatment of chronic pain — and subsequent substitution for opioids — suggests that cannabis may play a harm-reduction role in the ongoing opioid dependence and overdose crisis,” said Philippe Lucas, Vice President, Patient Research and Access at Tilray, who is also the lead investigator of TOPS. “While the cannabis substitution effect for prescription drugs has been identified and assessed via cross-sectional and population-level research, this study provides a granular individual-level perspective of cannabis substitution for prescription drugs and associated improvement in quality of life over time.”